PO

Patrick O'Neill

Partner @ Medtech Advantage Fund | Venture Capital Investments

Greater Boston

Invests in

  • Min Investment:

    $150,000.00
  • Max Investment:

    $7,000,000.00
  • Target Investment:

    $3,500,000.00

Work Experience

  • Partner

    2022

    MedTech Advantage Fund I (MTAF) focuses on venture investing in a broad selection of early and growth stage medtech companies. The Fund invests in selected graduates of MedTech Innovator (MTI), the world’s largest accelerator for medical devices, digital health, biotech tools, and diagnostic companies. The Fund leverages its unique access to MTI’s deal flow ecosystem of 500+ medtech experts, including large strategic medtech manufacturers.

  • Member

    2022

    Executive Forum is a highly engaged community of executives from leading corporations who share a passion for "what's next" to drive the business growth of tomorrow. Since its formation in 1995, the Executive Forum has grown to over 400 members who are the top-most leaders at market moving companies, run portfolios for the most innovative PE firms and serve as directors on boards — public, private and non-profit. Admission to the Executive Forum is based upon a rigorous nomination and review process. By design, approximately half the EF members are President/CEOs, and the others are at the COO, CFO, CMO, CIO and VP levels.

2020 - 2022

  • Board Member

    2020 - 2022

  • Managing Director, Venture Capital Investments

    2008 - 2022

    I led investments in the clean tech, life sciences, industrial tech and enterprise software sectors. My responsibilities include managing due diligence teams, negotiating terms, syndicating investors and serving on the target companies' Boards of Directors. I currently serve on the Boards of several portfolio companies and advise five early stage technology companies.

  • Board Observer

    2020 - 2021

2019 - 2021

  • Board Observer

    2019 - 2021

2019 - 2021

  • Board Member

    2019 - 2021

2018 - 2021

  • Board Member

    2018 - 2021

2017 - 2021

  • Member Board Of Directors

    2017 - 2021

    Landsdowne Labs is the newest spin out from the Langer Labs at MIT and the Karp Labs at Harvard. Through the use of advanced materials science, we are solving problems that others are not. We are focused on developing advanced materials for injury prevention, to bring solutions to a set of patients that are often overlooked: children.

2017 - 2021

  • Member, Board of Directors

    2017 - 2021

    Shoreline Biome’s mission is to develop leading-edge microbiome technologies and products and bring this innovative discovery technology to new and experienced microbiome investigators.